Cargando…

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression

Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizuno, Tomoko, Inoshita, Naoko, Fukuhara, Noriaki, Tatsushima, Keita, Takeshita, Akira, Yamada, Shozo, Nishioka, Hiroshi, Takeuchi, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943369/ https://www.ncbi.nlm.nih.gov/pubmed/34471015 http://dx.doi.org/10.2169/internalmedicine.6314-20

Ejemplares similares

Challenges in the functional diagnosis of thyroid nodules before surgery for TSH-producing pituitary adenoma
por: Tatsushima, Keita, et al.
Publicado: (2021)

Cushing’s Disease
por: Nishioka, Hiroshi, et al.
Publicado: (2019)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
por: Rossi, Valentina, et al.
Publicado: (2019)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

SAT-301 Relationship Between Clinicopathological Aspects and MSH6/MSH2 and PD-L1 Expressions in Clinically Nonfunctioning Pituitary Adenomas
por: Uraki, Shinsuke, et al.
Publicado: (2020)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Pasireotide treatment in Cushing’s disease: A single tertiary center’s experience
por: ŞAHİN, Serdar, et al.
Publicado: (2021)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Pasireotide—a novel somatostatin receptor ligand after 20 years of use
por: Bolanowski, Marek, et al.
Publicado: (2022)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes
por: Uraki, Shinsuke, et al.
Publicado: (2020)

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
por: Wolin, Edward M, et al.
Publicado: (2015)

Endoscopic Endonasal Surgery for Subdiaphragmatic Type Craniopharyngiomas
por: NISHIOKA, Hiroshi, et al.
Publicado: (2018)

Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis
por: Zhao, Nairui, et al.
Publicado: (2020)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
por: Barbot, Mattia, et al.
Publicado: (2022)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Tumor Shrinkage by Metyrapone in Cushing Disease Exhibiting Glucocorticoid-Induced Positive Feedback
por: Tsujimoto, Yasutaka, et al.
Publicado: (2021)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

MON-435 The Responsiveness To Ddavp Test Predicts Usp8 Mutation In Patients With Cushing's Disease
por: Shichi, Hiroki, et al.
Publicado: (2019)

Clinical Characteristics of Streptococcus Pneumoniae Meningoencephalitis after Transsphenoidal Surgery: Three Case Reports
por: KOBAYASHI, Nobuyuki, et al.
Publicado: (2014)

Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients: Classification according to Hormone Production and Cytokeratin Distribution
por: Mori, Ryosuke, et al.
Publicado: (2013)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?
por: Wong, Mimi, et al.
Publicado: (2021)

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
por: Oziel-Taieb, Sandrine, et al.
Publicado: (2022)

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
por: Fleseriu, Maria, et al.
Publicado: (2019)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Preoperative detection of functional somatostatin receptors in a patient with an insulinoma
por: Oguni, Kohei, et al.
Publicado: (2023)

Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
por: Yedinak, Chris G., et al.
Publicado: (2017)

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
por: Lacroix, André, et al.
Publicado: (2019)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease
por: Araki, Takako, et al.
Publicado: (2021)

Diagnostic Usefulness of 3 Tesla MRI of the Brain for Cushing Disease in a Child
por: Ono, Erina, et al.
Publicado: (2011)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant
por: Ramalingam, Sendhilnathan, et al.
Publicado: (2021)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9j7ucj04uqvdajrjvt93bs9iov